THE CONCEPT OF A STEPWISE APPROACH TO TREATING NONSPECIFIC PAIN IN THE LOWER BACK


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper discusses the choice of an optimal mode to relieve pain syndrome on an exacerbation of chronic musculoskeletal pain in the back. It highlights the possibility of using a stepwise approach: therapy is started from the least effective doses of nonsteroidal anti-inflammatory drugs (NSAIDs) and, if required, switched to other NSAIDs, a combination of the latter with other non-drug and drug treatments, including those with myorelaxants, antidepressants, and GABAergic agents.

Full Text

Restricted Access

About the authors

A. Karneev

N.I. Pirogov Russian National Research Medical University, Moscow

E. Solovyeva

N.I. Pirogov Russian National Research Medical University, Moscow

Email: ellasolovieva@yandex.ru

References

  1. Kinkade S. Evaluation and treatment of acute low back pain // Am. Fam. Physician. - 2007; 75: 1181-8, 1190-2.
  2. Borenstein D. Эпидемиология этиология, диагностическая оценка и лечение поясничной боли // Межд. мед. журн. - 2000; 35: 36-42.
  3. McCarberg B: Acute back pain: benefits and risks of current treatments // Curr. Med. Res. Opin. - 2010; 26 (1): 179-90.
  4. Подчуфарова Е.В., Яхно Н.Н. Боль в спине / М.: ГЭОТАР-Медиа, 2010; 368 с.
  5. Costa Lda C, Maher C., McAuley J. et al. Prognosis for patients with chronic low back pain: inception cohort study // BMJ. - 2009; 339: b3829.
  6. Freburger J., Holmes G., Agans R. et al. The rising prevalence of chronic low back pain // Arch. Intern. Med. - 2009; 169 (3): 251-8.
  7. Henschke N., Maher C., Refshauge K. et al. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study // BMJ. -2008; 337: a171.
  8. Павленко С.С., Денисов В.Н., Фомин Г.И. Организация медицинской помощи больным с хроническими болевыми синдромами / Новосибирм, 2002; 221 с.
  9. Carson J., Keefe F., Goli Vet al. Forgiveness and chronic low back pain: a preliminary study examining the relationship of forgiveness to pain, anger, and psychological distress // J. Pain. - 2005; 6 (2): 84-91.
  10. Duffy R. Low Back Pain: An Approach to Diagnosis and Management // Prim. Care Clin. Office Pract. - 2010; 37: 729-41.
  11. Wall P., Melzack R. Textbook of pain. 4th еd. - Edinburgh: Churchill Livingstone, 1999; р. 1143-53.
  12. Вейн А.М. Болевые синдромы в неврологической практике // М.: Медпресс-информ, 2001.
  13. Кукушкин М.Л., Хитров Н.К. Общая патология боли. М.: Медицина-2004.- 144 с.
  14. Haldeman S. Low back pain. Current physiologic concepts // Neurol.Clin. -1999; 17 (1): 1-15.
  15. Haroutiunian S., Drennan D., Lipman A. Topical NSAID therapy for musculoskeletal pain // Pain Medicine. - 2010; 11: 535-49.
  16. Machado L., Kamper S., Herbert R. et al. Analgesic effects of treatments for non-specific low back pain: a meta-analysis of placebo-controlled randomized trials // Rheumatology. - 2009; 48: 520-7.
  17. Roelofs P., Deyo R., Koes B. et al. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review // Spine. - 2008; 33: 1766-74.
  18. Omoigui S. The biochemical origin of pain: the origin of all pain is inflammation and the inflammatory response. Part 2 of 3 - inflammatory profile of pain syndromes // Med. Hypothes. - 2007; 69: 1169-78.
  19. Rannou F., Ouanes W., Boutron I. et al. High-sensitivity C-reactive protein in chronic low back pain with vertebral end-plate Modic signal changes // Arthritis. Rheum. - 2007; 57: 1311-5.
  20. Burke J., Watson R., McCormack D. et al. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators // J. Bone Joint. Surg. Br. - 2002; 84: 196-201.
  21. Ohtori S., Inoue G., Ito T. et al. Tumor necrosis factor-immunoreactive cells and PGP 9.5-immunoreactive nerve fibers in vertebral endplates of patient with discogenic low back pain and modic type 1 or type 2 changes on MRI // Spine. -2006; 31: 1026-31.
  22. Насонов Е.Л. Применение нестероидных противовоспалительных препаратов: терапевтические перспективы // РМЖ. - 2002; 10 (4): 206-12.
  23. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase // JAMA. - 2006; 13 (296): 1-12.
  24. Неспецифическая боль в нижней части спины. Диагностика, лечение, предупреждение / М.: КомплектСервис, 2008; 70 с.
  25. Euller-Ziegler L.,Velicitat P., Bluhmki E. et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration // Inflam. Res. - 2001; 50 (1): 5-9.
  26. Zeidler H., Kaltwasser J., Leonard J. et al. Prescription and Tolerability of Meloxicam in Day-to-Day Practice: Postmarketing Observational Cohort Study of 13,307 Patients in.
  27. Davies N., Skjodt N. Clinical pharmacokinetics of meloxicam: a cyclooxygenase-2 preferential non-steroidal anti-inflammatory drug // Clin. Pharmacokinet. - 1999; 36: 115-26.
  28. Цветкова Е.С., Панасюк Е.Ю., Иониченок Н.Г. и др. Перспективы применения ингибиторов циклооксигеназы-2 при остеоартрозе // Consilium Medicum. - 2004; 6 (2): 100-5.
  29. Dequeker J., Hawkey С., Kahan A. et al. Improvement in gastrointestinal tolerability on the selective cyclooxygenase (COX)-2 inhibitor meloxicam, compared with piroxicam: results of the safety and Efficacy Large scale Evalution of COX inhibiting Therapies (SELECT) trial in osteoarthritis // Br. J. Rheaumatol. - 1998; 37: 946-51.
  30. Hawkey С., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large Scale International Study Safety Assessment // Br. J. Rheaumatol. - 1988; 37: 937-45.
  31. Singh G., Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal complication: pooled analysis of 27039 patients: the results of the IMPROVE trial // EULAR Congress. - 2001, Prague.
  32. Combe B., Velicitat P., Garson N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients // Inflam. Res. - 2001; 50 (Suppl.1): S10-6.
  33. Vidal L., Kneer W., Baturone M. et al. Meloxicam in acute episodes of softtissue rheumatism of the shoulder // Inflam. Res. - 2001; 50 (Suppl. 1): S24-9.
  34. Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях // Тер. арх. -2004; 12: 78-80.
  35. Алексеев В.В. Применение мелоксикама в лечении люмбоишиалгического синдрома // РМЖ. - 2003; 7 (11): 416-8.
  36. Вознесенский А.Г. Клиническая фармакология нестероидных противовоспалительных средств. Волгоград, 1999.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies